Jennifer A. Marks

5.8k total citations · 1 hit paper
28 papers, 3.7k citations indexed

About

Jennifer A. Marks is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jennifer A. Marks has authored 28 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Jennifer A. Marks's work include Lung Cancer Treatments and Mutations (7 papers), Vector-borne infectious diseases (3 papers) and Viral Infections and Vectors (3 papers). Jennifer A. Marks is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Vector-borne infectious diseases (3 papers) and Viral Infections and Vectors (3 papers). Jennifer A. Marks collaborates with scholars based in United States, Mexico and Canada. Jennifer A. Marks's co-authors include Thomas Moritz, William C. Duckworth, Domenic J. Reda, Peter D. Reaven, Nicholas Emanuele, Carlos Abraira, Grant D. Huang, Madeline McCarren, Franklin J. Zieve and Stephen N. Davis and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Applied and Environmental Microbiology.

In The Last Decade

Jennifer A. Marks

24 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

2008 3.4k citations William C. Duckworth, Carlos Abraira et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer A. Marks United States	11	2.7k	821	640	598	359	28	3.7k
Roberto Miccoli Italy	31	1.4k 0.5×	586 0.7×	545 0.9×	828 1.4×	332 0.9×	124	3.5k
Gregory Fulcher Australia	26	1.5k 0.6×	403 0.5×	206 0.3×	641 1.1×	340 0.9×	74	2.3k
José Gerardo González‐González Mexico	25	1.3k 0.5×	595 0.7×	213 0.3×	573 1.0×	219 0.6×	126	2.6k
Laurence Duvillard France	34	1.5k 0.5×	555 0.7×	719 1.1×	911 1.5×	454 1.3×	128	3.3k
Farooq Syed United States	30	1.3k 0.5×	544 0.7×	358 0.6×	765 1.3×	382 1.1×	63	2.9k
Xiaojing Ma China	33	1.6k 0.6×	1.3k 1.6×	535 0.8×	703 1.2×	842 2.3×	211	4.3k
Irina Shalaurova United States	21	1.1k 0.4×	551 0.7×	477 0.7×	838 1.4×	506 1.4×	43	2.4k
Joachim Beige Germany	26	674 0.2×	433 0.5×	960 1.5×	375 0.6×	228 0.6×	112	2.4k
Etie S. Moghissi United States	19	3.3k 1.2×	751 0.9×	269 0.4×	569 1.0×	182 0.5×	31	3.6k
Antonino Di Pino Italy	29	899 0.3×	377 0.5×	517 0.8×	571 1.0×	311 0.9×	81	2.2k

Countries citing papers authored by Jennifer A. Marks

Since Specialization

Citations

This map shows the geographic impact of Jennifer A. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer A. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer A. Marks more than expected).

Fields of papers citing papers by Jennifer A. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer A. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer A. Marks. The network helps show where Jennifer A. Marks may publish in the future.

Co-authorship network of co-authors of Jennifer A. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer A. Marks. A scholar is included among the top collaborators of Jennifer A. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer A. Marks. Jennifer A. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Florez, Narjust, Nicole R. LeBoeuf, Julia Rotow, et al.. (2025). Mitigation and management of adverse events associated with amivantamab therapy. The Oncologist. 30(7).

Marks, Jennifer A., et al.. (2024). Precision Immuno-Oncology in NSCLC through Gender Equity Lenses. Cancers. 16(7). 1413–1413. 2 indexed citations

Marks, Jennifer A., Nishant Gandhi, Balázs Halmos, et al.. (2024). Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology. Lung Cancer. 196. 107935–107935. 2 indexed citations

Marks, Jennifer A., Jaeil Ahn, Joshua E. Reuss, et al.. (2024). Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma. Clinical Lung Cancer. 26(3). 165–167.

Marks, Jennifer A., Nishant Gandhi, Balázs Halmos, et al.. (2023). Updated molecular analysis of MET exon 14skippingmutations (METex14) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9095–9095. 2 indexed citations

Marks, Jennifer A., et al.. (2023). TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews. 60. 101055–101055. 10 indexed citations

Marks, Jennifer A. & Stephen V. Liu. (2023). NSCLC With Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Case Report. JTO Clinical and Research Reports. 4(6). 100521–100521. 1 indexed citations

Piotrowska, Zofia, Elaine Shum, Ying Liu, et al.. (2023). Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.. Journal of Clinical Oncology. 41(16_suppl). 9108–9108. 4 indexed citations

Marks, Jennifer A., et al.. (2022). Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report. JTO Clinical and Research Reports. 3(12). 100428–100428. 9 indexed citations

10.

Marks, Jennifer A., et al.. (2022). Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class. Current Oncology Reports. 24(12). 1829–1841. 9 indexed citations

11.

Marks, Jennifer A., Jun‐Jie Yin, Balázs Halmos, et al.. (2022). Analysis of MET exon 14skippingmutations in non–small cell lung cancer (NSCLC) by histology and specific mutation.. Journal of Clinical Oncology. 40(16_suppl). 9119–9119.

12.

Marks, Jennifer A., Jeffrey M. Switchenko, Conor Steuer, et al.. (2021). Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. JCO Oncology Practice. 17(3). e313–e322. 17 indexed citations

13.

Marks, Jennifer A., et al.. (2021). Nivolumab-associated cutaneous T-cell lymphoma. JAAD Case Reports. 9. 39–41. 5 indexed citations

14.

Flórez, Hermes, Peter D. Reaven, Gideon Bahn, et al.. (2015). Rosiglitazone treatment and cardiovascular disease in the V eterans A ffairs D iabetes Trial. Diabetes Obesity and Metabolism. 17(10). 949–955. 18 indexed citations

15.

Duckworth, William C., Carlos Abraira, Thomas Moritz, et al.. (2008). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine. 360(2). 129–139. 3364 indexed citations breakdown →

16.

Lovrich, Steven D., et al.. (2000). Evaluation of Whole-Cell and OspC Enzyme-Linked Immunosorbent Assays for Discrimination of Early Lyme Borreliosis from OspA Vaccination. Journal of Clinical Microbiology. 38(1). 313–317. 21 indexed citations

17.

Callister, Steven M., et al.. (1998). Borreliacidal Antibody Production against Outer Surface Protein C ofBorrelia burgdorferi. The Journal of Infectious Diseases. 178(3). 733–741. 47 indexed citations

18.

Gregory, Richard L., et al.. (1997). Effect of exercise on milk immunoglobulin A. Medicine & Science in Sports & Exercise. 29(12). 1596–1601. 29 indexed citations

19.

Marks, Jennifer A., et al.. (1995). Effect of Water Flow Rates in Hatching Jars to Control Fungal Infections of Rainbow Trout Eggs. The Progressive Fish-Culturist. 57(3). 226–230. 13 indexed citations

20.

Yang, Vina W., Jennifer A. Marks, Brian Davis, & Thomas W. Jeffries. (1994). High-efficiency transformation of Pichia stipitis based on its URA3 gene and a homologous autonomous replication sequence, ARS2. Applied and Environmental Microbiology. 60(12). 4245–4254. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact